Escape of tumor cells outside the ovarian capsule accounts for a significant percentage of treatment failures in patients with ovarian malignancies. [1] [2] [3] Identification of mechanisms promoting tumor cell invasion may help direct creation of new therapies that can arrest local invasion and metastatic spread of disease.
The serine protease matriptase was isolated as a type II transmembrane serine protease expressed in breast carcinoma [4] [5] [6] and subsequently cloned, 7 and the gene sequence was identified as ST14/SNC19. 8 Recent study in the prostate cancer cell line PC-3 also demonstrated the presence of a membrane-type serine protease, MT-SP1, which is identical to matriptase. 9 The gene sequence for matriptase has also been cloned as TADG-15, a member of a series of tumor-associated genes, expressed in ovarian carcinomas. 10, 11 Latent urokinase plasminogen activator (uPA) and prohepatocyte growth factor (pro-HGF) are substrates for matriptase. 12, 13 Both substrates participate in neoplastic invasion, most notably in the plasminmediated remodeling of the tumor extracellular matrix. The binding of uPA to its receptor increases the proliferation of human ovarian cancer cells in vitro.
14 Recent studies show that the active form of HGF stimulates the in vitro chemotaxis, motility, and proliferation of ovarian carcinoma cells. 15, 16 In the present study, we evaluated the expression of matriptase in 164 ovarian tumors using tissue microarrays. Immunohistochemistry studies in tissue microarray slides are more reliable than studies in individual slides because all tissues in each array slide are prepared and stained under the same conditions and are analyzed simultaneously. 17 In a series of patients with ovarian tumors, we compared immunostaining scores for matriptase among different histological types of ovarian tumors. Our findings demonstrate for the first time that matriptase is overexpressed in many malignant ovarian tumors.
Materials and methods
Paraffin-embedded tumor tissues were retrieved and tissue microarray slides were constructed according to a previously published method. 18 The tissue microarray slides consisted of samples from 164 patients with primary ovarian neoplasms including 84 with serous adenocarcinomas (mean age 57), 23 with mucinous adenocarcinomas (mean age 48), 10 with endometrioid adenocarcinomas (mean age 42), six with yolk sac tumors (mean age 22), 12 with clear cell carcinomas (mean age 48), six with dysgerminomas (mean age 12), eight with granulosa cell tumors (mean age 43), four with primary transitional cell carcinomas (mean age 51), five with fibromas (mean age 42), and six with Brenner tumors (mean age 57).
All tumors were pathologically staged according to the TNM and FIGO stage systems. Stage T1 was defined as a tumor limited to ovaries. Stage T2 was defined as a tumor involving one or both ovaries with pelvic extension. Stage T3 was defined as tumor involving one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis.
Immunohistochemistry
Tissue microarray sections were dewaxed in xylene, rehydrated in alcohol, and immersed in 3% hydrogen peroxide for 10 min to suppress endogenous peroxidase activity. Antigen retrieval was performed by heating (1001C) each section for 30 min in 0.01 mol/l sodium citrate buffer (pH 6.0). After three rinses (each for 5 min) in phosphate-buffered saline (PBS), sections were incubated for 2 h at room temperature with a rabbit anti-human matriptase/ ST14 antibody (1:100; BETHYL Laboratories, Montgomery, TX, USA) diluted in PBS. After three washes (each for 5 min) in PBS, sections were incubated with horseradish peroxidase-labeled mouse anti-rabbit immunoglobulin (DAKO, Glostrup, Denmark) for 1 h at room temperature. After three additional washes, peroxidase activity was developed with diaminobenzidine at room temperature.
For evaluation of immunoreactivity and histological appearance, all tissue microarray experiments were repeated 3 times and the slides were examined and scored by two authors concurrently. The intensity of cytoplasmic and membranous immunostaining of tumor cells was scored on a scale of 0 (no staining) to 4 (strongest intensity), and the percentage of tumor cells with cytoplasmic or membranous staining at each intensity was estimated. The percent of cells (from 0 to 100) at each intensity was multiplied by the corresponding immunostaining intensity (from 0 to 4) to obtain an immunostaining score ranging from 0 to 400.
Statistical Analysis
All results are expressed as mean7standard error of the mean (s.e.m.). The immunostaining score of matriptase for different types of ovarian tumors was compared with the score for normal ovarian fibrovascular tissue. Statistical analysis was performed using Student's t-test between groups. A P-value less than 0.05 was considered to be statistically significant. SigmaState software (Jandel Scientific, USA) was used to perform linear regression testing to analyze the relationship between matriptase immunostaining scores and clinicopathological parameters.
Results

Matriptase Expression in Ovarian Tumors
The histology of the hematoxylin and eosin-stained ovarian tumors, including serous adenocarcinoma, mucinous adenocarcinoma, clear cell carcinoma, transitional cell carcinoma, endometrioid adenocarcinoma, yolk sac tumor, Brenner tumor, granulosa cell tumor, and dysgerminoma was confirmed by two pathologists (Figure 1) .
Among the 164 ovarian tumors, matriptase immunoreactivity was seen on the cell surface and in the cytoplasm of tumor cells, but not on surrounding stromal cells or in the extracellular matrix (Figure 2) . Immunostaining scores for matriptase in ovarian tumors ranged from a high of 361728 for mucinous adenocarcinoma to a low of 271 for Brenner tumor. Data are presented in Table 1 . All 84 serous adenocarcinomas and 23 mucinous adenocarcinomas were strongly (intensity score greater than or equal to 3) and diffusely (490% tumor cells) positive for matriptase. The matriptase scores in ovarian tumors were significantly higher than in their nontumor counterparts (304726 for serous adenocarcinoma; 361728 for mucinous adenocarcinoma; 254717 for endometrioid adenocarcinoma; 205719 for yolk sac tumor; 162716 for clear cell carcinoma; 109711 for dysgerminoma; 10579 for granulosa cell tumor; and 226718 for transitional cell carcinoma). Expression of matriptase in fibroma and Brenner tumor was not increased.
Correlation of Matriptase Immunostaining Scores with Clinicopathological Features
In Figure 3 , there were 40 cases of stage T1, 34 cases of stage T2, and 10 cases of stage T3 serous adenocarcinoma. Of the 84 cases of serous adenocarcinoma, 46 were stage N0 and 38 were stage N1. The immunostaining scores for matriptase in serous adenocarcinoma showed significant correlation with TNM stage and FIGO stage. However, there were no significant relationships between matriptase immunostaining scores and clinicopathological features in mucinous adenocarcinoma, endometrioid adenocarcinoma, yolk sac tumor, clear cell carcinoma, dysgerminoma, granulosa cell tumor, and transitional cell carcinoma (data not shown).
Discussion
The human gene for matriptase is located within chromosome 11q24-q25. 8 Loss of heterozygosity (LOH) in this chromosome 11 region has been shown in ovarian epithelial cancers including serous adenocarcinoma and mucinous adenocarcinoma, [19] [20] [21] and LOH of 11q24-q25 has been associated with poor survival of patients with ovarian epithelial cancers. 19, 20 Although frequent LOH of 11q24-q25 has also been identified in colorectal carcinoma, no correlation with patient's survival was found. 22 LOH of 11q22-24 in cervical carcinomas and LOH of 11q22-11qter in breast cancers have also been observed and these findings suggest that this region may harbor a tumor-associated gene common to many types of human carcinomas. [23] [24] [25] In fact, because of matriptase's ability to cleave and activate growth factors and other serine proteases thought to be involved in cancer progression, matriptase has been implicated as a potential proinvasion and metastasis factor. In support of this hypothesis, our results demonstrated that significantly elevated matriptase immunostaining scores were found in serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, yolk sac tumor, clear cell carcinoma, dysgerminoma, granulosa cell tumor, and transitional cell carcinoma. This observation may suggest that matriptase has an important role in the clinical aggressiveness of these malignant ovarian tumors.
Matriptase immunostaining scores in serous adenocarcinoma were significantly correlated with the TNM stage and FIGO stage. However, there were no significant correlations between matriptase immunostaining scores and clinicopathological features in mucinous adenocarcinoma, endometrioid adenocarcinoma, yolk sac tumor, clear cell carcinoma, dysgerminoma, granulosa cell tumor, and transitional cell carcinoma. Lack of correlation may due to the limited number of cases in our study; future efforts will be directed at confirming matriptase's role in tumor progression and assessing the mechanism by which it contributes to the other invasive phenotypes of ovarian tumors. Recent advance in the tissue microarray technique has created a powerful tool for evaluating tumors simultaneously with histological and immunohistochemical analyses. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Previous studies of individual cases limited the value of stain intensity-based immunohistochemical quantitation because of the instability of the signal generated by chemical reaction under different environmental conditions. 17, [26] [27] [28] However, immunohistochemistry studies using tissue microarray technique are more reliable than studies involving individual tissues because all tissues are processed under the same immunostaining conditions and analyzed simultaneously in a tissue microarray slide. 17, [26] [27] [28] Thus, the immunostaining scores used in our study are a better reflection of the relative level of matriptase protein expression in tumors.
In conclusion, we demonstrated for the first time that matriptase is expressed in many malignant ovarian tumors, except fibroma and Brenner tumor. Increased expression of matriptase in serous adenocarcinoma has significant clinicopathological relationships to the aggressiveness seen with this tumor. Our results add considerable support to the likelihood that matriptase acts as a novel biomarker for diagnosis and treatment of malignant ovarian tumors. 
